Zydis

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1998-2011
01219982011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Selegiline is a monoamine-B specific inhibitor used to treat Parkinson's disease. A Zydis sublingual preparation has more… (More)
  • table 1
Is this relevant?
2007
2007
OBJECTIVE The objective of this study was to compare the efficacy of a disintegrating tablet of ondansetron (ODT) and the… (More)
Is this relevant?
Review
2007
Review
2007
Selegiline, a selective monoamine oxidase-B inhibitor, has been used for decades in the treatment of Parkinson's disease. The… (More)
Is this relevant?
2004
2004
Zydis selegiline dissolves on contact with saliva and undergoes pregastric absorption. This minimizes first-pass metabolism and… (More)
Is this relevant?
2003
2003
Seven randomised comparative studies were conducted in healthy volunteers to compare the pharmacokinetic and pharmacodynamic… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2003
2003
Three studies were performed using a fast dissolving formulation of selegiline hydrochloride designed for buccal absorption… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
Review
1998
Review
1998
  • H D Seager
  • The Journal of pharmacy and pharmacology
  • 1998
Many patients find it difficult to swallow tablets and hard gelatin capsules and do not take their medication as prescribed. It… (More)
Is this relevant?